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Introduction
Anthracylines, produced mainly by soil dwelling Gram-positive bacteria of the genus Streptomyces, are aromatic polyketides that often exhibit a high cytostatic potency.
Several members of this group, for example epirubicin and doxorubicin, belong to the most used anti-cancer agents worldwide [1] . Anthracycline biosynthesis in Streptomyces starts with the production of the polyketide scaffold, which is formed by iterative additions of malonate extender units to acetate or propionate primers by type II polyketide synthase in concert with cyclases, aromatases and ketoreductases [2] . The aglycone backbone is further modified by tailoring enzymes including hydroxylases, methylases and aminotransferases, leading to the large diversity of these metabolites. An important class of tailoring enzymes are the glycosyltransferases, as glycosylation of the carbon skeleton is required in many cases to form the biologically active polyketides [3, 4] . These glycosyltransferases use nucleotide diphosphate sugars as donors, typically TDP-conjugated sugars, with a significantly greater diversity amongst the sugaracceptors [5] .
Streptomyces nogalater produces the aromatic polyketide nogalamycin (Figure 1, 1) , which contains the carbohydrate moieties nogalose attached to carbon 7 and nogalamine attached to carbon 1 [6] . The attachment of nogalamine to the aglycone is highly remarkable as it involves the formation of a carbon-carbon bond linking atoms C5´´ of the sugar and C2 of the polyketide scaffold. A second link is formed via an O-glycosidic bond to carbon 1 of nogalamine. Attachment of sugar moieties to natural products via C-C bonds has been described in a few cases, for instance urdamycin [7] , gilvocarcin [8] , hedamycin [9] and granaticin [10] , but the combination of both types of linkages in nogalamycin is rather unique and poses interesting questions about the order of the attachment and the chemistry of this glycosylation step.
The gene cluster responsible for the biosynthesis of nogalamycin in S. nogalater has been cloned and the functions of most of the encoded enzymes have been annotated by sequence comparisons and/or subsequent biochemical and structural studies [11] [12] [13] [14] [15] . The cluster contains three genes that code for glycosyltransferases, snogD, snogE and snogZ, related to each other by amino acid sequence identities of around 30 %. A recent study showed that SnogE is responsible for the transfer of nogalose to the C-7 hydroxyl group of nogalamycinone (Figure 1, 2) , whereas SnogD is involved in the transfer of the nogalamine moiety to the glycosylated metabolic intermediate 3´,4´-demethoxynogalose-1-hydroxynogalamycinone (Figure 1, 3) [15] . The glycosyltransferase SnogZ appears to be redundant as it is not necessary for the heterologous formation of double glycosylated anthracyclines in the expression host S.
albus.
Sequence comparisons of SnogD (UniProt Q9RN61) with related enzymes show that it belongs to the glycosyltransferase type 1 family [16] . These enzymes display the GT-B fold [17] and are characterized by a S N 2-type mechanism of sugar transfer with accompanying inversion of the anomeric configuration at C1 of the donor-sugar. Here we present the X-ray crystal structure of SnogD, in the apo-form and in complex with the nucleotide 2´-deoxyuridine-5´-diphosphate (dUDP). We further report the results of in vitro and in vivo mutagenesis studies of the conserved active site residues His25 and His301.The structural and functional data are consistent with crucial roles of these residues in the mechanism of SnogD as a catalytic base and in nucleotide-sugar binding, respectively.
Results

Structure determination of SnogD
The crystal structure of recombinant SnogD, comprising residues 13-390 of the native enzyme, was determined in two different space groups to resolutions of 2.6 and 2.7 Å, respectively ( Table 1) . Crystals of wild-type SnogD (SnogD-wtdUDP) of sufficient diffraction quality (< 3 Å resolution) could not be reproduced despite numerous attempts.
Reductive methylation of the protein sample proved critical for reproducibility of crystallisation and diffraction quality of the crystal. Chemical modification of SnogD resulted in a mass of 42023.5 Da determined by electrospray mass spectrometry, which compares well to the theoretical mass (42024.0 Da) of the SnogD construct including eight methyl groups. This data thus suggest almost complete di-methylation of the Nterminal nitrogen atom and the four lysine residues.
The structure of the enzyme was determined in three different forms, wild-type SnogD in space group P2 1 2 1 2 and methylated SnogD in space groups P2 1 2 1 2 and P2, respectively (SnogD-mdUDP and SnogD-m). The orthorhombic space group contains two chains in the asymmetric unit (51 % solvent content). The refined models comprise all residues of the construct (13-390), with a few exceptions. Weak or no electron density is observed for two loop regions in most of the chains of all three reported structures, which were thus modelled to various extents. These peptide segments are in the vicinity of the Table 1 .
Overall structure of SnogD
Structure of the subunit: SnogD displays the twin-domain architecture of the GT-B fold, consisting of two Rossman-fold domains with the active site located at the domain interface ( Figure 3 ). The N-terminal domain (residues 1-209) consists of a seven-stranded parallel β-sheet, eight α-helices and two 3 10 -helices. The sheet itself is sandwiched between four of the helices on one side and three helices on the other side. The Cterminal domain (residues 228-390) is of similar topology with a six-stranded parallel β-sheet flanked by six α-and four 3 10 -helices. The last C-terminal helix, with a kink between residues Glu374-Pro377, a common feature of the GT-B fold, crosses over to complete the N-terminal domain through residues Pro378-Gly390.
Structural relationships to related proteins:
A search for structural homologues of SnogD using the DALI-server [18] resulted in several GT-1 glycosyltransferases with significant structural similarity despite low sequence homology. The closest structural relatives are CalG3 [19] , Z-score 42.5, r.m.s.d 2.3 Å, 38 % sequence identity; UrdGT2 The α-phosphate is located at the N-terminal end of the helix (303-315) and is linked via hydrogen bonds to the amide groups of Ser304 and Gly305 ( Figure 3 ). Both residues are part of the conserved diphosphate-binding "PPi-motif" [26] represented in SnogD by GGSG ( Figure S1 ). The highly conserved His301 is appropriately positioned to form hydrogen bonds to both α-and β-phosphate groups. A modest movement would bring the β-phosphate group into hydrogen bonding distance to main chain amide and side chain hydroxyl of Ser236. Such an interaction is observed in one of the nucleotide-binding subunits of SnogD-mdUDP.
In UDP-utilizing GTs the recognition of the ribose moiety is provided by hydrogen bonds of a glutamic acid residue located in the α-helix directly following the PPi-motif [24, 27, 28] . In SnogD, this glutamic acid is replaced by Thr309, which does not interact with the deoxyribose group. Instead the 3'-hydroxyl group of the carbohydrate moiety forms a hydrogen bond to the side chain of Asn212. The different mode of hydrogen bonding interactions of the deoxyribose group in SnogD compared to the UDP-donor specific glycosyltransferases results in a difference in conformation of parts of the interdomain linker (residues 210-227). These conformational differences can be described as a shift of this peptide segment closer to the nucleotide binding site ( Figure   S2 ), a feature also recently observed in TDP-donor specific SpnG [21] .
Another sequence motif, D/E-Q, frequently encountered in the nucleotide binding region of glycosyltransferases [29] and involved in hydrogen bonds to the C2´´-C4´´ hydroxyl groups of the donor-sugar substrate is not conserved in SnogD ( Figure S1 ). However, nogalamine is restricted by the covalent link to the dinucleotide, the small pocket for the carbohydrate moiety present in SnogD, and the requirement for the C1´-hydroxyl to be in an axial orientation so that glycosyl transfer can occur.
In the absence of experimental data on SnogD-acceptor substrate complexes the precise orientation of acceptor substrates in the binding pocket of SnogD is more difficult to define, due to the large size of the hydrophobic pocket and the lack of structural data for the FL1 loop. Acceptor substrate binding to SnogD most likely involves hydrophobic residues lining the cleft between the domains and closure of the FL1 loop over the acceptor substrate as seen in CalG3 [22] . The acceptor substrate 3 (Figure 1 ) can be modeled in the predominantly hydrophobic substrate cleft in such a way that the C1 hydroxyl group of the acceptor is located suitably to act as nucleophile and attack the C1 atom of the activated nogalamine sugar (Figure 6 ). In this model His25 is close to the C1 hydroxyl group of the aglycon, which is the attacking nucleophile in the glycosyl-transfer reaction.
In vitro characterization of active site mutants of SnogD
Based on the modeled ternary complex of SnogD with the nucleotide-sugar donor and acceptor substrates, we selected the highly conserved residues His25 and His301 ( Figure   S1 ) as target for site directed mutagenesis. The mutations His25Ala, His25Asn and His301Ala were introduced and the mutant proteins purified according to the protocol used for wild-type SnogD. The CD spectra of mutants and wild-type enzyme were very similar, indicating that the mutants were correctly folded. The natural sugar donor TDP-nogalamine was not available and the enzymatic reaction was therefore studied in the reverse direction using the assay described previously [15] ( Figure 7A ). The in vitro assays with the mutants His25Ala, His25Asn and His301Ala showed a significant reduction of UDP-dependent deglycosylation of nogalamycin F 4 to 3 to 1.5 -2.4 % of the wild type enzyme activity ( Figure 7B and Table 2 ).
In vivo studies of active site mutants
In order to probe the glycosyltransfer reaction in the forward direction, the mutated genes were expressed in vivo in S. albus using a two-plasmid system. The polyketide acceptor 3 and the nucleotide diphosphate deoxysugar donor substrates were produced using cosmid pSno∆gD, which contains the majority of the nogalamycin gene cluster and from which snogD has been deleted [15] . The native and mutated snogD genes were expressed in the heterologous host using the high copy number vector pIJ486 from their own promoter sequences as described in the experimental section. The production profiles of the strains indicated that formation of the aminoglycosylated SnogD reaction product, nogalamycin R 5 ( Figure 8A ), was impaired in the mutant strains ( Figure 8B ), consistent with the in vitro activity measurements.
Discussion
Previous studies on the glycosylation reactions in nogalamycin biosynthesis have shed some light on the order of these steps and the enzymes involved [15] . SnogD can utilize both TDP and UDP in the in vitro assay, the deglycosylation of 4 [15] .
This is consistent with structural data, as the binding pocket could accommodate the uracil and thymidin rings. SnogD however lacks the glutamic acid residue proposed to be characteristic for UDP-donor specific glycosyltransferases [27] and thus might not be able to discriminate efficiently between UDP-and TDP-donors.
Since attempts to obtain crystals of ternary complexes of SnogD with acceptor substrates were not successful, the structure of SnogD with bound dUDP was used as templates to model the Michaelis complex of SnogD with UDP-nogalamine and 3. This model suggests one active site residue, His25 close to the C1´´ atom of the activated sugar that might be able to facilitate the enzymatic reaction. This residue could be involved in proton abstraction, thus enhancing nucleophilicity of the acceptor substrate and facilitating the attack onto the C1´´ of the donor-sugar and subsequent glycosyl transfer.
Replacements of His25 by alanine and asparagine result in mutants that are severely impaired in catalytic activity in vitro. Analysis of the production profiles in vivo using these SnogD mutants show the same trend with a significant reduction in the amounts of 5 produced. These data demonstrate a critical role of this residue in the enzyme reaction and are consistent with a function as catalytic base.
Another histidine residue, His301 close to the diphosphate group of the donor sugar, is also essential for catalysis as substitution of this residue by alanine results in significant loss of enzyme activity in vitro. This residue is involved in binding of the diphosphate group and could further stabilize the negative charge developing at the β-phosphate of the leaving group [32] . These two residues are conserved in many glycosyltransferases and their counterparts have been implicated in the catalytic mechanisms of these enzymes [19, 24, [27] [28] [29] 33] .
The evidence for the function of SnogD as a glycosyltransferase involved in the formation of the C1-O-glycosidic bond to nogalamine is now rather compelling. It is however much less clear whether or not SnogD is directly involved in the formation of the carbon-carbon linkage between C5´´ of nogalamine and the C2 atom of the polyketide. This reaction requires formally abstraction of hydrogen, and the structure of SnogD does not contain any catalytic groups and/or cofactors that might support such chemistry. This step in nogalamycin biosynthesis remains enigmatic and most likely requires another enzyme, either working in concert with SnogD or acting after the glycosyltransfer reaction.
Materials and methods
Cloning, expression and purification of recombinant SnogD
The cloning, expression and purification of recombinant SnogD was performed as described previously [15] . In short, eight different constructs were designed, all with an N-terminal His-tag, amplified from genomic Streptomyces nogalater DNA by PCR and cloned using ligation-independent (LIC) cloning [34] . The production of one construct, comprising residues 13-390, using E. coli as expression host followed a protocol described elsewhere [15] . Na 2 SeO 4 and 4µM FeCl 3 . Recombinant SnogD was purified using affinity, anionexchange and size exclusion chromatography. The purity of the protein was monitored by SDS-PAGE and the identity of the recombinant protein was confirmed by electrospray mass spectrometry (ES-MS).
Mutagenesis
Residues for mutagenesis were selected based on the structure of SnogD and protein sequence alignment to structural homologues ( Figure S1 ). The mutations were introduced by PCR using the full-length expression plasmid, encoding residues 1-390 of SnogD cloned as described previously [15] , as template using primers containing the mutations (His25Alaf 5´- 
Reductive methylation of SnogD
Purified SnogD was diluted to a final concentration of 1 mg/ml in a solution containing 45 mM Na 3 PO 4 , 0.3 M NaCl, and 10 % (v/v) glycerol pH 8.0. Reductive methylation was performed based on a protocol described previously [35] , with two exceptions; the formaldehyde solution was prepared freshly by dissolving paraformaldehyde in 50 mM Na 3 PO 4 pH 8.0 and heating to 333 K during 4 hours, and the methylation reaction was quenched by addition of 1 M glycine to a final concentration of 0.1 M. After filtration methylated SnogD was purified using anion exchange and size exclusion chromatography. The extent of methylation of SnogD was determined by ES-MS.
Crystallization of SnogD
Wild-type SnogD (SnogD-wtdUDP) was crystallized by hanging drop vapour diffusion against a reservoir containing 26 % (w/v) PEG 3350 and 0.1 M citrate pH 5.2. Droplets of the protein solution (10 mg/ml SnogD-wtdUDP in 50 mM Tris pH 7.4, 0.2 M NaCl)
were mixed with equal volumes of the reservoir solution. Crystals belonging to space group P2 1 2 1 2 appeared after three days equilibration at 293 K.
Since diffraction quality crystals were difficult to reproduce using wild type enzyme, screening for crystallization conditions was repeated with methylated SnogD, which in combination with streak seeding reproducibly yielded diffraction quality crystals at two conditions. The SnogD-mdUDP and SnogD-m data were collected from crystals obtained Crystallographic data were collected at 100 K and at a wavelength of 0.934 Å at beamline ID14-EH1 of the European Synchrotron Radiation Facility (Grenoble, France), to a resolution of 2.6 Å. Crystals of methylated SnogD were cryo-protected using mineral oil.
Data were collected from two crystals, to 2.7 Å (SnogD-mdUDP) and 2.6 Å (SnogD-m) resolution, respectively, at a wavelength of 1.072 Å at beamline ID23-EH1 at ESRF (Grenoble, France). Data processing was performed using the programs MOSFLM and SCALA from the CCP4 package [36] . Statistics of the diffraction data sets are given in Table 1 .
The SnogD-m crystal belonged to space group P2 1 2 1 2 with similar unit cell dimension as the SnogD-wt crystal, containing two enzyme subunits per asymmetric unit. In contrast, the SnogD-mdUDP crystal belongs to space group P2 with 4 molecules (2 dimers) per asymmetric unit.
The crystal structure of SnogD-wtdUDP was determined by molecular replacement using PHASER [37] and an ensemble of monomer structures of five homologues enzymes (PDB accession codes 1F0K, 1NLM, 2IYA, 2P6P, and 3D0Q) as search model, of which CalG3 from Micromonospora echinospora shows the highest sequence identity to SnogD (36 %). The structures of methylated SnogD were determined by molecular replacement using PHASER (SnogD-mdUDP) or MOLREP [38] (SnogD-m) and the refined ligand-free subunit of SnogD-wt as search model.
Model building and refinement was performed using WinCOOT [39] and REFMAC5 Table 1 .
The atomic coordinates and crystallographic data have been deposited with the Protein Data Bank under accession numbers 4AMB (SnogD-wtdUDP), 4AMG (SnogD-m), and
Quaternary structures, crystal packing and interfaces were analyzed using the PISAserver at the European Bioinformatics Institute [25] . Database searches for structural homologues were carried out using Dali [18] . Sequence alignments were performed using ClustalW [41] . Figures were prepared with PyMol [42] .
In vitro enzyme assays
Full-length SnogD and point mutants were used for the activity assays. Since activated TDP-nogalamine or UDP-nogalamine were not available as sugar donors the reaction was monitored in the reverse direction, using UDP as acceptor and 4 as donor using the protocol described previously [15] . In short 8.1 µg of SnogD was added to 40 µl of a mixture of 20 mM UDP as acceptor-and 0.5 mM 4 as donor-substrate in 50 mM Tris, 200 mM NaCl, pH 7.4 and incubated in the dark at 295 K for 13h. The reactions were quenched by addition of chloroform and the anthracyclines were extracted from the resulting mix of chloroform and water. The chloroform phases were analyzed by HPLC to detect glycosyl transferase activity, which was defined as the ratio between formed product 3 over remaining substrate 4, after correction for 3 present in minor amounts in the substrate solution.
In vivo activity assays
The mutated snogD genes were moved as NdeI-EcoRI fragments to digested and CIAPtreated pBluescript SK(-) (Stratagene; La Jolla, CA, USA) harbouring the PCR amplified and sequenced snogD promoter region. The PCR was carried out using pSnogaori [15] as the template and the following primers with vector compatible restriction sites (EcoRI, HindIII) and added NdeI-site downstream of the promoter region: FWgDp AATAAGCTTAGGTCTCCGGGCGGGTCA REVgDp:
TTAGAATTCTTACATATGGACGGCGCCTTCTGTTGC. The promoter and gene region were moved as an EcoRI-HindIII fragment (1.5 kb) to a digested and CIAP-treated pIJ486-vector [43] . The plasmids were amplified in S. lividans TK24, verified by digestion analysis and moved to S. albus/pSnoΔgD by PEG-induced protoplast transformation [44] . The wild type SnogD plasmid was constructed as described earlier [15] .
For analysis of the activity of SnogD and mutated SnogD the strains were cultivated in 250 ml Erlenmeyer-flasks with 30 ml of NoS-soyE1 [15] supplemented with thiostrepton (Calbiochem; San Diego, CA, USA 50 μg ml -1 ) and apramycin (Sigma-Aldrich, St.
Louis, MO, USA 50 μg ml -1 ) for 5 days at 303 K in vigorous shaking. The produced metabolites were collected by binding to Amberlite® XAD-7 (2 days, Rohm and Haas, Philadelphia, PA, USA, 20 g l -1 ) after which the medium was decanted and the XAD-7
was washed with water. The metabolites were extracted with MeOH and filtered (0.2 μm PTFE, VWR, Radnor, PA, USA) prior to analysis by HPLC (Shimadzu SCL-10Avp;
Kyoto, Japan) with a reversed-phase column (SunFireTM C18 3.5 μm 2.1 x 150 mm, Waters, Milford, MA, USA) using a gradient from 15% acetonitrile in 0.1% formic acid to 100% acetonitrile.
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